RE:Commercial Scale Operational Update, CBGA Production UpdateIt all boils down to top and bottom lines. There is no evidence yet of any significant demand for rare cannabinoids and whether this is even a profitable venture. Yes, lofty sales projections to 2025 seem to be a dime a dozen. But, where the beef? We'll see in the next quarter. InMed and Willow are still getting hammered. Contrarians can buy but better to board the train leaving the station as they say.